|
answer text |
<p>The United Kingdom Government has made clear that it wishes to see the existing
reciprocal healthcare arrangements with the European Union continued after the UK
leaves the EU. All UK-insured residents, including sufferers of rare diseases, benefit
from the reciprocal healthcare arrangements currently in place and the Government
is working to ensure this access to healthcare in EU member states continues on the
same terms as they do now after the UK leaves the European Union.</p><p>During negotiations
with the EU on the Withdrawal Agreement, the UK has therefore been seeking to protect
the healthcare arrangements currently set out in EU Regulations 883/2004 and 987/2009.
In the meantime, while the UK remains a member of the EU, it will continue to respect
the rights and honour the obligations of EU membership and so the current arrangements
remain in place.</p><p>The UK is recognised internationally for its expertise and
excellence in the field of rare diseases. In this regard, the UK Government has three
key principles in its approach to the development of a post-Exit relationship with
the EU:</p><p>- That no patient should be disadvantaged;</p><p>- That the UK should
continue to play a leading role promoting and ensuring public health, both in Europe
and around the world; and</p><p>- Industry must be able to get their products into
the UK market as quickly and simply as possible, with the UK and Europe at the forefront
of medical innovation.</p><p> </p><p><strong> </strong></p>
|
|